×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
ASRT – assertio holdings, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
ASRT
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
3/16
11:05 pm
asrt
Assertio Holdings Inc (ASRT) Q4 2025 Earnings Call Highlights: Navigating Challenges with ... [Yahoo! Finance]
Low
Report
Assertio Holdings Inc (ASRT) Q4 2025 Earnings Call Highlights: Navigating Challenges with ... [Yahoo! Finance]
3/16
06:15 pm
asrt
Assertio Q4 Earnings Call Highlights [Yahoo! Finance]
Low
Report
Assertio Q4 Earnings Call Highlights [Yahoo! Finance]
3/16
06:07 pm
asrt
Assertio Holdings, Inc. (ASRT) Q4 2025 Earnings Call Transcript [Seeking Alpha]
Low
Report
Assertio Holdings, Inc. (ASRT) Q4 2025 Earnings Call Transcript [Seeking Alpha]
3/16
06:04 pm
asrt
Assertio outlines $110M–$125M 2026 revenue target with Rolvedon at the core while shifting business development approach [Seeking Alpha]
Low
Report
Assertio outlines $110M–$125M 2026 revenue target with Rolvedon at the core while shifting business development approach [Seeking Alpha]
3/16
05:57 pm
asrt
Assertio (ASRT) Q4 2025 Earnings Call Transcript [Yahoo! Finance]
Low
Report
Assertio (ASRT) Q4 2025 Earnings Call Transcript [Yahoo! Finance]
3/16
05:32 pm
asrt
Assertio Holdings Non-GAAP EPS of -$1.06 beats by $0.74, revenue of $13.52M beats by $7.32M [Seeking Alpha]
Low
Report
Assertio Holdings Non-GAAP EPS of -$1.06 beats by $0.74, revenue of $13.52M beats by $7.32M [Seeking Alpha]
3/16
04:37 pm
asrt
Assertio: Q4 Earnings Snapshot [Yahoo! Finance]
Medium
Report
Assertio: Q4 Earnings Snapshot [Yahoo! Finance]
3/16
04:33 pm
asrt
Assertio Reports Fourth Quarter and Full Year 2025 Financial Results [Yahoo! Finance]
Medium
Report
Assertio Reports Fourth Quarter and Full Year 2025 Financial Results [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
3/16
05:07 pm
asrt
Form 10-K Assertio Holdings, Inc. For: Dec 31
Low
Report
Form 10-K Assertio Holdings, Inc. For: Dec 31
3/16
04:07 pm
asrt
Form 8-K Assertio Holdings, Inc. For: Mar 16
Medium
Report
Form 8-K Assertio Holdings, Inc. For: Mar 16
3/3
07:27 pm
asrt
Form 4 Assertio Holdings, Inc. For: Mar 02 Filed by: Schlessinger Sam
Low
Report
Form 4 Assertio Holdings, Inc. For: Mar 02 Filed by: Schlessinger Sam
3/3
07:25 pm
asrt
Form 4 Assertio Holdings, Inc. For: Mar 02 Filed by: Patel Ajay
Low
Report
Form 4 Assertio Holdings, Inc. For: Mar 02 Filed by: Patel Ajay
3/3
07:24 pm
asrt
Form 4 Assertio Holdings, Inc. For: Mar 02 Filed by: Schwichtenberg Paul
Low
Report
Form 4 Assertio Holdings, Inc. For: Mar 02 Filed by: Schwichtenberg Paul
3/3
07:23 pm
asrt
Form 4 Assertio Holdings, Inc. For: Mar 02 Filed by: Reisenauer Mark L
Low
Report
Form 4 Assertio Holdings, Inc. For: Mar 02 Filed by: Reisenauer Mark L
2/24
06:02 pm
asrt
Form 4 Assertio Holdings, Inc. For: Feb 21 Filed by: Schlessinger Sam
Low
Report
Form 4 Assertio Holdings, Inc. For: Feb 21 Filed by: Schlessinger Sam
2/24
06:02 pm
asrt
Form 4 Assertio Holdings, Inc. For: Feb 21 Filed by: Patel Ajay
Low
Report
Form 4 Assertio Holdings, Inc. For: Feb 21 Filed by: Patel Ajay
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
12/12
Assertio Therapeutics Announces Sale of Gralise® for Total Transaction Value of $127.5 Million
48.2%
2/6 Assertio Therapeutics Announces Sale of NUCYNTA® Franchise to Collegium Pharmaceutical for $375.0 Million 46.2%
3/11 Assertio Therapeutics Announces Offer to Purchase All of Its Issued and Outstanding 2.50% Senior Convertible Notes Due 2021 and 5.00% Senior Convertible Notes Due 2024 22.4%
12/13 Hedge Funds Are Crazy About Assertio Therapeutics, Inc. (ASRT) [Yahoo! Finance News] 15.7%
3/25 Form SC TO-I/A Assertio Therapeutics, Filed by: Assertio Therapeutics, Inc 14.9%
11/12 Form SC 13G Assertio Therapeutics, Filed by: D. E. SHAW & CO, L.P. 11.2%
8/20 Form 4 Assertio Therapeutics, For: Aug 19 Filed by: HIGGINS ARTHUR J 10.9%
2/19 Assertio Therapeutics Announces Repurchase of Approximately $188.0 Million of its Outstanding Convertible Debt 9.5%
4/24 Form 8-K Assertio Therapeutics, For: Apr 22 9.1%
10/5 How Does Assertio Therapeutics, Inc. (NASDAQ:ASRT) Affect Your Portfolio Volatility? [Yahoo! Finance News] 9.0%
2/6 Assertio Therapeutics Announces Sale of NUCYNTA® Franchise to Collegium Pharmaceutical for $375.0 Million 46.2%
3/11 Assertio Therapeutics Announces Offer to Purchase All of Its Issued and Outstanding 2.50% Senior Convertible Notes Due 2021 and 5.00% Senior Convertible Notes Due 2024 22.4%
12/13 Hedge Funds Are Crazy About Assertio Therapeutics, Inc. (ASRT) [Yahoo! Finance News] 15.7%
3/25 Form SC TO-I/A Assertio Therapeutics, Filed by: Assertio Therapeutics, Inc 14.9%
11/12 Form SC 13G Assertio Therapeutics, Filed by: D. E. SHAW & CO, L.P. 11.2%
8/20 Form 4 Assertio Therapeutics, For: Aug 19 Filed by: HIGGINS ARTHUR J 10.9%
2/19 Assertio Therapeutics Announces Repurchase of Approximately $188.0 Million of its Outstanding Convertible Debt 9.5%
4/24 Form 8-K Assertio Therapeutics, For: Apr 22 9.1%
10/5 How Does Assertio Therapeutics, Inc. (NASDAQ:ASRT) Affect Your Portfolio Volatility? [Yahoo! Finance News] 9.0%
TOP News Decliners
8/9
Assertio Therapeutics, Inc (ASRT) Q2 2019 Earnings Call Transcript [The Motley Fool]
-45.9%
3/9 Q4/2019 12/31/2019 EPS -0.140 ZacksConsensus -0.220 ActVsEst 0.080 - Beat -30.8%
10/21 Assertio Therapeutics Provides Regulatory Update on Long-Acting Cosyntropin -24.9%
8/20 Assertio Therapeutics to Present at the 17th Annual Morgan Stanley Global Healthcare Conference -17.4%
10/30 Ceridian HCM Holding, BJ's Wholesale Club Holdings Set to Join S&P MidCap 400; Oceaneering International, Covetrus to Join S&P SmallCap 600 -15.0%
11/6 Assertio Therapeutics, Inc. 2019 Q3 - Results - Earnings Call Presentation [Seeking Alpha] -12.2%
3/2 Assertio Therapeutics to Report Fourth Quarter and Full Year 2019 Financial Results After the Close of Markets on Monday, March 9, 2020 -11.8%
1/13 Form 8-K Assertio Therapeutics, For: Jan 10 -9.4%
4/21 Form 425 Assertio Therapeutics, Filed by: Assertio Therapeutics, Inc -7.9%
5/9 Form 4 Assertio Therapeutics, For: May 09 Filed by: MCKEE WILLIAM -7.7%
3/9 Q4/2019 12/31/2019 EPS -0.140 ZacksConsensus -0.220 ActVsEst 0.080 - Beat -30.8%
10/21 Assertio Therapeutics Provides Regulatory Update on Long-Acting Cosyntropin -24.9%
8/20 Assertio Therapeutics to Present at the 17th Annual Morgan Stanley Global Healthcare Conference -17.4%
10/30 Ceridian HCM Holding, BJ's Wholesale Club Holdings Set to Join S&P MidCap 400; Oceaneering International, Covetrus to Join S&P SmallCap 600 -15.0%
11/6 Assertio Therapeutics, Inc. 2019 Q3 - Results - Earnings Call Presentation [Seeking Alpha] -12.2%
3/2 Assertio Therapeutics to Report Fourth Quarter and Full Year 2019 Financial Results After the Close of Markets on Monday, March 9, 2020 -11.8%
1/13 Form 8-K Assertio Therapeutics, For: Jan 10 -9.4%
4/21 Form 425 Assertio Therapeutics, Filed by: Assertio Therapeutics, Inc -7.9%
5/9 Form 4 Assertio Therapeutics, For: May 09 Filed by: MCKEE WILLIAM -7.7%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: